Sanofi obtained exclusive worldwide rights to Kali Therapeutics' KT501, a Phase 1 tri-specific T-cell engager targeting CD3/CD19/BCMA for B-cell autoimmune diseases. Kali receives $180M upfront/near-term plus up to $1.05B in milestones and tiered royalties. Deal reflects Sanofi's continued push into immune-depletion strategies for autoimmune disease.
Key facts
AnnouncedMar 23, 2026
ClosedMar 23, 2026
Deal value$1.2B
Deal typeLicensing/Option
Therapeutic areaB-cell-mediated autoimmune diseases (first-in-human in rheumatoid arthritis)
IndicationsB-cell-mediated autoimmune diseases (first-in-human in rheumatoid arthritis)
Key assetsKT501 (tri-specific T-cell engager CD3 x CD19 x BCMA)
MechanismTri-specific IgG-like T-cell engager binding CD3, CD19, and BCMA to deplete a broad range of B-cell populations